The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of interest: (1) in the monitoring of patients (in place including a possible repetition renal biopsy); (2) to guide treatment decisions and (3) in clinical research, as an outcome (in substitution for the occurrence of kidney failure) in therapeutic trials IgA nephropathy. This research project constitutes the first step in validating these antibodies biomarker of IgA nephropathy and its main objective is to study the performance of the blood levels of anti-hinge region antibodies in the diagnosis of progressive forms of histologically IgA nephropathy as defined by the Renal Risk Absolute. The secondary objectives of this project are to establish a bio-collection that will allow us to search for other prognostic factors (genetic, cellular and serum) of IgA nephropathy and to evaluate the performance of Renal Absolute risk by integrating Oxford score, the new international histological classification.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
68
dosage of anti-hinge region antibodies
CH d'ANNECY
Annecy, France
CH d'ANNONAY
Annonay, France
CH de BOURG EN BRESSE
Bourg-en-Bresse, France
CH de CHAMBERY
Chambéry, France
CHU de CLERMONT-FERRAND
Clermont-Ferrand, France
CHU de DIJON
Dijon, France
CHU de GRENOBLE
Grenoble, France
CH du PUY EN VELAY
Le Puy-en-Velay, France
Hôpital Edouard. HERRIOT
Lyon, France
Centre Hospitalier de Lyon Sud
Pierre-Bénite, France
...and 5 more locations
serum concentration of anti-hinge region antibodies (mg/ml)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.